Helena Escuin-Ordinas

8.1k total citations · 1 hit paper
19 papers, 2.1k citations indexed

About

Helena Escuin-Ordinas is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Helena Escuin-Ordinas has authored 19 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 7 papers in Immunology and 6 papers in Molecular Biology. Recurrent topics in Helena Escuin-Ordinas's work include Cancer Immunotherapy and Biomarkers (7 papers), CAR-T cell therapy research (6 papers) and Immunotherapy and Immune Responses (6 papers). Helena Escuin-Ordinas is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), CAR-T cell therapy research (6 papers) and Immunotherapy and Immune Responses (6 papers). Helena Escuin-Ordinas collaborates with scholars based in United States, United Kingdom and Spain. Helena Escuin-Ordinas's co-authors include Antoni Ribas, Begonya Comin-Anduix, Thomas G. Graeber, Roger S. Lo, Willy Hugo, Siwen Hu‐Lieskovan, Jesse M. Zaretsky, Ángel García-Díaz, Lu Sun and Giulia Parisi and has published in prestigious journals such as Nucleic Acids Research, PLoS ONE and Cancer Research.

In The Last Decade

Helena Escuin-Ordinas

19 papers receiving 2.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

2017 1.3k citations Ángel García-Díaz, Daniel Sanghoon Shin et al. Cell Reports profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Helena Escuin-Ordinas United States	13	1.4k	1.0k	644	273	175	19	2.1k
Jesse M. Zaretsky United States	8	1.5k 1.1×	1.3k 1.3×	518 0.8×	278 1.0×	183 1.0×	16	2.1k
Ilaria Grazia Zizzari Italy	25	1.1k 0.8×	782 0.8×	663 1.0×	315 1.2×	185 1.1×	61	1.9k
Catherine Sabatos-Peyton United States	13	1.1k 0.8×	1.2k 1.2×	475 0.7×	233 0.9×	137 0.8×	23	2.1k
Cristina Puig-Saus United States	13	1.4k 1.0×	1.0k 1.0×	704 1.1×	247 0.9×	180 1.0×	18	2.0k
Heidi Harjunpää Finland	14	1.3k 0.9×	934 0.9×	458 0.7×	393 1.4×	195 1.1×	20	2.1k
M. Ángela Aznar Spain	18	1.5k 1.1×	1.5k 1.5×	715 1.1×	185 0.7×	201 1.1×	23	2.5k
Bilal A. Siddiqui United States	11	824 0.6×	802 0.8×	440 0.7×	233 0.9×	155 0.9×	48	1.7k
Lawrence P. Andrews United States	11	1.3k 0.9×	1.1k 1.1×	392 0.6×	244 0.9×	159 0.9×	14	1.9k
David Y. Oh United States	18	1.0k 0.7×	1.1k 1.1×	918 1.4×	299 1.1×	171 1.0×	43	2.4k
Todd D. Armstrong United States	29	2.0k 1.4×	2.3k 2.2×	843 1.3×	230 0.8×	232 1.3×	54	3.3k

Countries citing papers authored by Helena Escuin-Ordinas

Since Specialization

Citations

This map shows the geographic impact of Helena Escuin-Ordinas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helena Escuin-Ordinas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helena Escuin-Ordinas more than expected).

Fields of papers citing papers by Helena Escuin-Ordinas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helena Escuin-Ordinas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helena Escuin-Ordinas. The network helps show where Helena Escuin-Ordinas may publish in the future.

Co-authorship network of co-authors of Helena Escuin-Ordinas

This figure shows the co-authorship network connecting the top 25 collaborators of Helena Escuin-Ordinas. A scholar is included among the top collaborators of Helena Escuin-Ordinas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helena Escuin-Ordinas. Helena Escuin-Ordinas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Rodríguez-Ruiz, María E., Paloma Sánchez‐Mateos, Maite Álvarez, et al.. (2023). Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control. Journal for ImmunoTherapy of Cancer. 11(1). e005011–e005011. 14 indexed citations

Kalbasi, Anusha, Fritz C. Eilber, Arun S. Singh, et al.. (2021). Abstract CT221: A phase I study of intratumoral BO-112 and nivolumab for resectable soft tissue sarcoma. Cancer Research. 81(13_Supplement). CT221–CT221. 2 indexed citations

Escuin-Ordinas, Helena, Yining Liu, Lu Sun, et al.. (2021). Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects. PLoS ONE. 16(6). e0252597–e0252597. 10 indexed citations

Zhu, Suwei, Shuoran Li, Helena Escuin-Ordinas, et al.. (2018). Accelerated wound healing by injectable star poly(ethylene glycol)-b-poly(propylene sulfide) scaffolds loaded with poorly water-soluble drugs. Journal of Controlled Release. 282. 156–165. 37 indexed citations

Nowicki, Theodore S., Helena Escuin-Ordinas, Earl Avramis, et al.. (2018). Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products. Journal of Immunotherapy. 41(5). 248–259. 2 indexed citations

García-Díaz, Ángel, Daniel Sanghoon Shin, Blanca Homet Moreno, et al.. (2017). Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. Cell Reports. 19(6). 1189–1201. 1327 indexed citations breakdown →

Zaretsky, Jesse M., Ángel García-Díaz, Daniel S. Shin, et al.. (2017). Abstract NG04: Mechanisms of resistance to anti-PD-1 immunotherapy through interferon pathway mutations. Cancer Research. 77(13_Supplement). NG04–NG04. 3 indexed citations

Ibarrondo, F. Javier, Begonya Comin-Anduix, & Helena Escuin-Ordinas. (2016). Tremelimumab: research and clinical development. OncoTargets and Therapy. 9. 1767–1767. 75 indexed citations

Tavaré, Richard, Helena Escuin-Ordinas, Stephen Mok, et al.. (2015). An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy. Cancer Research. 76(1). 73–82. 237 indexed citations

10.

Atefi, Mohammad, Bjoern Titz, Earl Avramis, et al.. (2015). Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma. Molecular Cancer. 14(1). 27–27. 51 indexed citations

11.

Shin, Daniel S., Ángel García-Díaz, Jesse M. Zaretsky, et al.. (2015). Innate resistance of PD-1 blockade through loss of function mutations in JAK resulting in inability to express PD-L1 upon interferon exposure. Journal for ImmunoTherapy of Cancer. 3(S2). 14 indexed citations

12.

Tavaré, Richard, Helena Escuin-Ordinas, Melissa McCracken, et al.. (2015). Detection of antibody therapy-induced anti-tumor immune responses using anti-CD8 immuno-pet. Journal for ImmunoTherapy of Cancer. 3(S2). 1 indexed citations

13.

Wong, Deborah J., Earl Avramis, Douglas Matsunaga, et al.. (2014). Exposure to a Histone Deacetylase Inhibitor Has Detrimental Effects on Human Lymphocyte Viability and Function. Cancer Immunology Research. 2(5). 459–468. 17 indexed citations

14.

Odon, Valerie, Garry A. Luke, Pablo de Felipe, et al.. (2013). APE-Type Non-LTR Retrotransposons of Multicellular Organisms Encode Virus-Like 2A Oligopeptide Sequences, Which Mediate Translational Recoding during Protein Synthesis. Molecular Biology and Evolution. 30(8). 1955–1965. 11 indexed citations

15.

Escuin-Ordinas, Helena, Mohammad Atefi, Yong Fu, et al.. (2013). COX‐2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors. Molecular Oncology. 8(2). 250–260. 31 indexed citations

16.

Escuin-Ordinas, Helena, Mark Elliott, Mohammad Atefi, et al.. (2013). PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody. Journal for ImmunoTherapy of Cancer. 1(1). 14–14. 14 indexed citations

17.

Yan, Fu, et al.. (2011). 2A peptides provide distinct solutions to driving stop-carry on translational recoding. Nucleic Acids Research. 40(7). 3143–3151. 111 indexed citations

18.

Comı́n-Anduix, Begoña, Hooman Sazegar, Thinle Chodon, et al.. (2010). Modulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma. PLoS ONE. 5(9). e12711–e12711. 23 indexed citations

19.

Comı́n-Anduix, Begoña, Thinle Chodon, Hooman Sazegar, et al.. (2010). The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations. Clinical Cancer Research. 16(24). 6040–6048. 111 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact